Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MIV-818 |
Synonyms | |
Therapy Description |
MIV-818 is a prodrug that is hydrolyzed in hepatocytes to troxacitabine triphosphate (TRX-TP), which may have immune modulating and anti-tumor effects (Mol Cancer Ther 2019;18(12 Suppl):Abstract nr C056.). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MIV-818 | MIV818|MIV 818 | MIV-818 is a prodrug that is hydrolyzed in hepatocytes to troxacitabine triphosphate (TRX-TP), which may have immune modulating and anti-tumor effects (Mol Cancer Ther 2019;18(12 Suppl):Abstract nr C056.). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03781934 | Phase Ib/II | MIV-818 | A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations | Active, not recruiting | GBR | ESP | BEL | 1 |